FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Media coverage

• Title	FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
  Media name/outlet	USA Life Sciences Database
  Country/Territory	Switzerland
  Date	15/02/21
  URL	www.usalifesciences.com/us/portal/news_details.php?news_id=23137351k$SnPoaWjSNZUJE&page_id=?next=1
  Persons	William Roberts

• Title	-FDA Approves G1 Therapeutics COSELA, the First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
  Media name/outlet	ENP Newswire
  Country/Territory	United Kingdom
  Date	15/02/21
  Persons	William Roberts